Artivion announced that it has completed the acquisition of Endospan Ltd., its long-standing partner focused on endovascular repair of aortic arch disease and developer of the NEXUS Aortic Arch System. Artivion funded the $135 million upfront net purchase price using its previously drawn $150 million delayed draw term loan. The transaction also includes potential additional consideration tied to commercial performance.
The acquisition follows the U.S. Food and Drug Administration’s approval of the premarket approval application for the NEXUS branched endovascular stent graft system in April 2026. Artivion had previously served as the exclusive distributor of the NEXUS System across EMEA since 2019.
According to the company, the acquisition strengthens its aortic arch portfolio by combining the NEXUS platform with its AMDS and ARCEVO LSA technologies. Artivion said the addition of Endospan also brings a pipeline of next-generation arch technologies currently under development, which the company expects will further expand its position in the aortic arch market.
KEY QUOTE:
“Our acquisition of Endospan and its NEXUS system completes our market-leading, three-pronged aortic arch portfolio. This technology, alongside AMDS and ARCEVO LSA, positions us at the forefront of this segment as the only company globally with a complete portfolio of aortic arch solutions. Further, NEXUS is a platform technology, not just a single product. With this acquisition, we are also adding a robust pipeline of next-generation arch technologies currently in development that we expect will further expand and strengthen our leadership position in the aortic arch market over time.”
Pat Mackin, Chairman, President, and Chief Executive Officer, Artivion
